Shopping Cart
- Remove All
Your shopping cart is currently empty
(393)
MAPKRas
Ras proteins are a class of small GTPases that serve as core regulatory factors within intracellular signalling networks. By switching between GDP and GTP states on the cell membrane, they modulate downstream pathways including MAPK/ERK and PI3K/AKT signalling, thereby influencing cellular proliferation, differentiation, and survival. In human tumours, mutations in Ras genes (KRAS, HRAS, NRAS) are extremely common, particularly KRAS, which is widely found in pancreatic, colorectal and lung cancers. These mutations typically result in Ras being perpetually activated, driving abnormal signalling and tumourigenesis.
RMC-6236
T746982765081-21-6
RMC-6236 is an orally effective and novel triple complex RAS (ON) MULTI inhibitor, which is a potent non covalent inhibitor of multiple RAS variants in GTP binding state. RMC-6236 has anti-tumor activity and can be used in research related to RAS driven tumors. With rich experience in compound synthesis, we can provide fast customized synthesis services for this product according to your research needs.
- $58
Size
QTY
RMC-9805
T782122922732-54-3
RMC-9805 is a novel, mutant-selective, covalent and oral KRASG12D (ON) inhibitor. A stable and high affinity triple complex is formed between RMC-9805, KRASG12D, and cyclophilin A, which inhibits signal transduction downstream of KRASG12D (ON) by disrupting its interaction with downstream effectors. RMC-9805 can induce cell apoptosis and promote tumor regression in preclinical KRASG12D tumor models. With rich experience in compound synthesis, we can provide fast customized synthesis services for this product according to your research needs.
- $129
Size
QTY
MRTX1133
Cited
T93032621928-55-8In house
MRTX1133 is a KRAS G12D inhibitor (KD=0.2 pM) that is potent, selective, and non-covalent. MRTX1133 exhibits inhibitory activity against KRAS G12D-mutated tumors, but not against KRAS wild-type tumors.
- $197
Size
QTY
CitedBI-2493
T720612937344-16-4In house
BI-2493 is a highly selective pan-KRAS inhibitor and structural analog of BI-2865.BI-2493 exhibits antitumor activity and inhibits tumor cell growth and can be used in the study of cancerous diseases.BI-2493 is a highly selective pan-KRAS inhibitor and structural analog of BI-2865.
- $629
Size
QTY
Adagrasib Cited
T83692326521-71-3
Adagrasib (MRTX849) is an orally active and selective covalent inhibitor of KRAS G12C. Adagrasib binds to the GDP state of the inactive conformation of KRAS G12C and inhibits KRAS and its downstream signaling. Adagrasib exhibits inhibitory activity against KRAS G12C mutant tumors.
- $59
Size
QTY
CitedDivarasib
T99722417987-45-0
Divarasib (GDC-6036) (GDC-6036) is an investigational, oral, high-potency and selective KRAS G12C inhibitor with an IC50 of < 0.01 μM. Divarasib irreversibly locks KRAS G12C oncoprotein in an inactive state and inhibits tumor cell growth. It is being investigated for use in solid tumors, including non-small cell lung and colorectal cancers and other types of cancer.
- $245
Size
QTY
BI-2865 Cited
T720622937327-93-8
BI-2865 is a non-covalent pan-KRAS inhibitor.BI-2865 binds to KRAS WT, G12C, G12D, G12V, and G13D mutants with KD values of 6.9, 4.5, 32, 26, and 4.3 nM, respectively.BI-2865 showed antiproliferative activity in BaF3 cells expressing KRAS G12C, G12D, or G12V mutants[1] . BI-2865 showed antiproliferative activity on BaF3 cells expressing KRAS G12C, G12D or G12V mutants, with an average IC50 value of approximately 140 nM.[1]
- $222
Size
QTY
CitedSotorasib Cited
T86842296729-00-3
Sotorasib (AMG-510) is an orally active and selective covalent inhibitor of KRAS G12C. Sotorasib binds to the GDP state of the inactive conformation of KRAS G12C and inhibits KRAS and its downstream signaling. Sotorasib exhibits inhibitory activity against KRAS G12C mutant tumors.
- $31
Size
QTY
Cited
T751312641998-63-0
RMC-6291 is an orally active, covalent inhibitor of KRAS G12C (ON) that forms a tri-complex within tumor cells between KRAS G12C (ON) and cyclophilin A (CypA), thereby preventing KRAS G12C (ON) from signaling via steric blockade of RAS effector binding and eliciting deep and durable suppression of RAS pathway activity in KRAS G12C tumor models [1].
- $162
Size
QTY
Glecirasib
T786512657613-87-9
Glecirasib (JAB-21822) is an orally active KRAS G12C inhibitor that selectively binds to and inhibits the activity of KRAS G12C mutants, thereby inhibiting KRAS G12C-dependent signaling. In animal models, KRAS G12C inhibitor 36 showed a favorable safety profile and potential to inhibit tumor growth.
- $113
Size
QTY
RMC-7977
T812632765082-12-8
RMC-7977 is a highly selective inhibitor of the active (GTP-bound) forms of KRAS, HRAS, and NRAS with anticancer activity for the study of solid tumors with KRAS G12C mutations.
- $257
Size
QTY
T2040833040175-17-2
AMG410 is a non-covalent, dual-modality KRAS inhibitor effective against both GDP (OFF) and GTP (ON) binding, with Kd (GDP) of 1 nM and Kd (GTP) of 22 nM, capable of blocking KRAS independently of the cell cycle. AMG410 does not affect HRAS and NRAS2, and exhibits high potency against KRAS G12D, G12V, G12C, G13D, and other mutants, with an IC₅₀ of 1–4 nM. It induces tumour regression and reduces phosphorylated ERK levels in KRAS-mutant cancer models.
- $337
Size
QTY
Digeranyl bisphosphonate
T12452878143-03-4In house
Digeranyl bisphosphonate (DGBP) is a potent geranylgeranyl pyrophosphate (GGPP) synthase inhibitor that impedes the geranyl pyrophosphorylation of Rac1 and induces autophagy without causing apoptosis.
- $263
Size
QTY
Atranorin
TN1413479-20-9
Atranorin shows significant antinociceptive and antiinflammatory activities, it has a relevant redox-active action, acting as a pro-oxidant or antioxidant agent depending on the radical, also, it will exert cytoprotective effects on cells under oxidative
- $68
Size
QTY
ML-210 Cited
T83751360705-96-9
ML-210 (CID 49766530) is a glutathione peroxidase 4 (GPX4) inhibitor (EC50=30 nM) that is covalent and selective. ML-210 has antitumor activity and induces ferroptosis.
- $34
Size
QTY
CitedLonafarnib
Cited
T6302193275-84-2
Lonafarnib (Sch66336) is an orally bioavailable FPTase inhibitor for H-ras, K-ras-4B, and N-ras (IC50: 1.9/5.2/2.8 nM).
- $41
Size
QTY
CitedBI-3406 Cited
T129792230836-55-0
BI-3406 is an orally active, highly potent and selective between KRAS and Son of Sevenless 1 (SOS1) interaction inhibitor(IC50 : 6 nM),with anticancer activity.
- $67
Size
QTY
CitedT861672543673-19-2
DCC-3116 is an orally active, selective and potent ULK1/2 inhibitor with anticancer activity.DCC-3116 inhibits autophagy and can be used in cancer research.
- $66
Size
QTY
N-Acetylneuraminic acid
T1638131-48-6
N-Acetylneuraminic acid (Acide aceneuramique) is a nine-carbon sialic acid monosaccharide commonly found in glycoproteins on cell membranes and in glycolipids such as gangliosides in mammalian cells. Studies have shown that N-Acetylneuraminic acid is biologically useful for neurotransmission, leukocyte extravasation, viral or bacterial infections, and carbohydrate-protein recognition.
- $48
Size
QTY
Rhosin hydrochloride
T167451281870-42-5
Rhosin hydrochloride is a specific inhibitor of the RhoA subfamily Rho GTPases and inhibits the RhoA-GEF interaction. Rhosin hydrochloride can significantly induce cell apoptosis without affecting cell cycle progression. [1]
- $162
Size
QTY
ACBI3
T855472938169-76-5
ACBI3 is a selective pan-KRAS degrader with anticancer activity that degrades oncogenic KRAS. ACBI3 inhibits the growth of most cancer cell lines driven by KRAS mutations.
- $272
Size
QTY
Paluratide
T796732676177-63-0
Paluratide (LUNA18) is a reversible cyclic peptide KRAS inhibitor with the advantages of oral availability and cell permeability for the treatment of kras-mutant cancers, which inhibits cancer cell proliferation by phosphorylating ERK and AKT, and also inhibits the interaction of RAS with guanine nucleotide exchange factors (GEFs).
- $1,180
Size
QTY
Ketoconazole Cited
T067965277-42-1
Ketoconazole (R-41400), a CYP3A4 inhibitor, is an imidazole anti-fungal agent.
- $31
Size
QTY
Cited Go to page 1
Page of 10
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.